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Abstract 
Antibody-based PET tracers are exceptionally well-suited for determination of the in vivo biodistribution 
and quantification of therapeutic antibodies. The continued expansion in antibody-based therapeutics has 
accordingly driven the development towards more robust conjugation strategies in order to reliably 
predict the performance of such agents. We therefore aimed to evaluate the effect of site-specific labeling 
by enzymatic remodeling on the stability, immuno-reactivity and tumor-targeting properties of the 
monoclonal antibody (mAb) trastuzumab and compare it to conventional, random labeling in a 
HER2-positive xenograft mouse model. 
Methods: Trastuzumab was conjugated with the p-SCN-Bn-Desferrioxamine (SCN-Bn-DFO) chelator 
randomly on lysine residues or site-specifically on enzymatically modified glycans using either 
β-galactosidase or endoglycosidase S2 prior to 89Zr radiolabeling. 89Zr-DFO-trastuzumab was injected 
into SK-OV-3 tumor-bearing NMRI nude mice. The antibody dose was titrated with either 100 µg or 500 
µg of unlabeled trastuzumab. Mice underwent small animal PET/CT imaging 24, 70 and 120 hours 
post-injection for longitudinal assessment. Parallel experiments were conducted with an isotype control 
matched antibody. In vivo imaging was supported by conventional ex vivo biodistribution and HER2 
immuno-histochemistry. Furthermore, site-specifically labeled 89Zr-DFO-trastuzumab was evaluated in a 
panel of subcutaneous patient-derived xenograft (PDX) models. Additionally, the affinity, in vitro stability 
and immuno-reactivity were assessed for all tracers. 
Results: Site-specific labeling significantly increased PET tumor uptake (One-way ANOVA, p<0.0001) at 
all time-points when compared to random labeling. Mean tumor uptakes were 6.7 ± 1.7, 13.9 ± 3.3 and 
15.3 ± 3.8 % injected dose per gram tissue (%ID/g) at 70 hours post-injection, for random, β-galactosidase 
or endoglycosidase S2 labeled probes, respectively. Co-injection with unlabeled trastuzumab increased 
the circulation time of tracers but did not alter tumor uptake notably. Site-specific probes presented with 
a superior in vitro stability and immuno-reactivity compared to the randomly labeled probe. Ex vivo 
biodistribution confirmed the data obtained by in vivo PET imaging, and site-specific 
89Zr-DFO-trastuzumab successfully detected HER2-positive tumors in PDX mouse models. 
Conclusion: 89Zr-DFO-trastuzumab is well-matched for specific immuno-PET imaging of HER2-positive 
tumors and site-specific labeling of trastuzumab by the SiteClickTM technology minimizes the impact of the 
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DFO chelator on immuno-reactivity, stability and biodistribution. These findings support further 
development of site-specifically radiolabeled mAbs for immuno-PET. 
Key words: Positron emission tomography (PET), immuno-PET, site-specific labeling, molecular imaging, HER2 
Introduction 
Given their extraordinary target-specificity, 
monoclonal antibodies (mAbs) have emerged as a 
particularly well-suited platform for development of 
positron emission tomography (PET) imaging agents. 
Such antibody-based PET tracers combine the 
non-invasive quantitative nature of PET with the high 
selectivity, stability and favorable pharmacokinetic 
properties of mAbs. PET imaging with radiolabeled 
mAbs (immuno-PET) serves diagnostic as well as 
therapeutic purposes [1,2], with the ability to image 
and track the biodistribution of therapeutic antibodies 
and radioimmunoconjugates. Furthermore, 
immuno-PET imaging agents are ideal for in vivo 
evaluation of biomarker expression providing 
phenotypic information related to primary and 
metastatic lesions, thus ultimately guiding therapy 
decisions.  
The relatively slow pharmacokinetics of intact 
antibodies necessitates a radioisotope with a suitable 
physical half-life, such as Zirconium-89 (89Zr, 
T1/2=78.4 hours). Zirconium-89 decays to yttrium-89 
via beta decay with 22.7 % positron emission. In 
addition to 511 keV annihilation radiation, the decay 
gives rise to a 99% abundant 909 keV gamma. The 
desferrioxamine (DFO) chelator [3] has long been the 
preferred choice for stable coupling of 89Zr to 
preclinical and clinical immuno-PET imaging agents 
[4–8]. The need for stable chelation chemistry in the 
development of 89Zr-immuno-PET imaging probes is 
highlighted by the fact that uncomplexed 89Zr 
localizes to bone in mice and thereby possibly delivers 
a high non-targeted radiation dose, which has led to a 
continued research into the development of improved 
chelating agents [9–11]. In addition, the majority of 
known chelator conjugation strategies rely on 
reactions with amino acids which can lead to an 
uneven and random distribution of chelates. Even 
conventional methodology for chelator conjugation to 
mAbs can suffer from several shortcomings such as 
potential loss of immuno-reactivity, inadequately 
defined conjugates as well as lack of reproducibility 
[12]. Together with the steady expansion and use of 
antibody-based therapies for cancer, such as 
antibody-drug-conjugates (ADCs) and 
radio-immunotherapy agents, this has increased 
attention towards alternative conjugation strategies 
such as site-specific conjugation [2,13,14]. 
Site-specific conjugation allows for a single, 
uniform product as opposed to a heterogeneous 
mixture of conjugates resulting from the conventional 
random conjugation methodology [15]. By harnessing 
an explicit site, distant from the antigen-binding 
region, the site-specific strategy offers stoichiometric 
control as well as minimal loss of immuno-reactivity. 
The impact of site-specific conjugation on in vivo 
behavior has been confirmed in multiple applications 
such as antibody-drug conjugation [16,17] and 
molecular imaging [12,18–21].  
Several technologies for site-specificity have 
emerged over the past years by utilizing approaches 
such as cysteine engineering [19,22], click chemistry 
[23,24] and glycan remodeling [25,26]. Cysteine 
engineering of antibodies is an elegant way of 
tailoring both the location and number of conjugates 
but is equally a complex and constrained system 
adding expense to the conjugation process. 
Remodeling of the heavy chain glycans of antibodies 
is an interesting platform offering highly specific 
conjugation distal to the antigen-binding region in a 
robust and reproducible manner [25–27]. By 
exploiting two conserved glycosylation sites on heavy 
chain glycans this site-specific modification 
(SiteClickTM) approach [25] is a robust technique that 
can be applied on various IgG’s across species while 
requiring only minimal optimization. In brief, the 
SiteClickTM radiolabeling procedure uses enzymatic 
processes to incorporate an activated azide into the 
heavy chain glycans enabling click-conjugation of a 
payload such as the DFO chelator.  
We hereby demonstrate the use of the 
SiteClickTM technology to the production of 
site-specifically labeled immuno-PET imaging probes 
and compare them to a conventional, randomly 
labeled probe. Given that trastuzumab (Herceptin®) 
is one of the most widely used mAbs in clinical 
oncology and our experience in trastuzumab 
radiolabeling [28], we chose HER2/trastuzumab as 
the model system to investigate the effect of 
site-specific labeling. We paired trastuzumab with 
89Zr to reach optimal target-to-background ratios and 
applied it to the HER2-positive SK-OV-3 ovarian 
adenocarcinoma mouse model. This site-specific 
conjugation methodology produced well-defined 
constructs with improved immuno-reactivity, 
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stability and tumor uptake when compared to their 
randomly labeled counterparts.  
Materials and Methods 
Cell culture and animal models 
SK-OV-3 ovarian adenocarcinoma cells (ATCC 
HTB-77, LGC standards) were cultured in McCoy’s 5a 
Modified Medium supplemented with 10% FBS and 
1% penicillin-streptomycin at 37 °C and 5% CO2. Cells 
were harvested in their exponential growth phase and 
resuspended 1:1 in complete growth media and 
MatrigelTM (BD Biosciences) at a concentration of 
5x107 cells/mL. 100 uL of the cell suspension (5x106 
cells/tumor) was injected subcutaneously into the 
flanks (2 tumors/mouse) above the hind limbs in 
7-week old female NMRI nude mice (Taconic, 
Denmark). Tumors were grown until ~ 200 mm3 prior 
to imaging experiments and mice were randomized 
into 11 groups (N=4/group).  
The ST562 (gastric), ST2789B (breast), ST518 
(breast), ST928B (breast) and ST1616B (breast) PDX 
models (START, San Antonio, TX, USA) were 
established by subcutaneous passage of tumor pieces 
(1 tumor/mouse) into the flanks in 7-week old female 
NMRI nude mice. All animal procedures were 
conducted with approval by the National Animal 
Experiments Inspectorate (license no. 
2016-15-0201-00920).  
Antibody conjugation and radiolabeling 
Trastuzumab (Herceptin®, Roche, Basel, 
Switzerland) was either site-specifically modified by 
enzymatic reactions or randomly conjugated to 
p-SCN-Bn-Desferrioxamine (SCN-Bn-DFO, 
Macrocyclics). β-(1-4) galactosidase, GalT enzyme and 
UDP-GalNAz substrate were obtained from Thermo 
Fisher Scientific (OR, USA) and endoglycosidase S2 
was purchased from Genovis (Lund, Sweden). 
One mg of purified trastuzumab was incubated 
for either 6 hours at 37 ⁰C with β-(1-4) galactosidase (8 
µL, 2U/mL) or 2 hours at 37 ⁰C with endoglycosidase 
S2 (5 µL) in a reaction volume of 100 µL. After 
incubation, GalT enzyme (20 µL, 2 mg/mL), 
UDP-GalNAz substrate (20 µL, 40 mM) and MnCl2 in 
0.1 M HCl (2 µL, 1 M) were added to a final reaction 
volume of 200 µL, and the mixture was incubated 
overnight at 30 ⁰C. Excess UDP-GalNAz and GalT 
enzyme were removed and the buffer was exchanged 
into Tris-buffered Saline (TBS) using Amicon ULTRA 
50 kD MW cut-off spin filters. Site-specifically 
modified trastuzumab was conjugated to DIBO-DFO 
(40 µL, 4 mM) in 35 molar excess overnight at 25 ⁰C 
and ultimately purified using Amicon ULTRA 50 kD 
MW cut-off spin filters. Accordingly, randomly 
labeled trastuzumab was prepared by incubating 5 
mg of purified trastuzumab (27.5 nmol, 170 µL) with 5 
molar excess DFO-Bz-NCS dissolved in DMSO in 0.1 
M NaHCO3 (1 hour, 37 ⁰C, pH=9.0) followed by PD-10 
purification (GE Healthcare, IL, USA) into PBS. 
Additionally, a final version of DFO-trastuzumab was 
prepared by treating 1 mg trastuzumab with 
endoglycosidase S2 followed by random conjugation 
according to the methods described above. Thus, four 
different conjugates of DFO-trastuzumab were 
obtained. Concurrently, an isotype control matched 
antibody (Human IgG1, #BE0297, BioXcell, USA) was 
either site-specifically conjugated by the endoS2 
method or randomly conjugated to DFO by the 
protocols described above. Aliquots of 200 µg of 
DFO-trastuzumab and DFO-IgG1 were stored until 
radiolabeling at -80 ⁰C. Degree of labeling (DOL) was 
determined for the following conjugates by mass 
spectrometry: random, β-Gal and endoS2 modified 
DFO-trastuzumab. 
89Zr-oxalate (PerkinElmer, the Netherlands) was 
neutralized to pH ~7 with 1 M Na2CO3 prior to 
labeling. 200 µg of modified and conjugated 
trastuzumab or IgG1 was incubated with 150 MBq 
neutralized 89Zr-oxalate (1 hour, 37 ºC, pH=7.0) 
followed by PD10 purification into PBS. The 
radiochemical yield and purity at end-of-synthesis 
(EOS) were determined by radio-thin-layer 
chromatography (radio-TLC) using an eluent of 50 
mM EDTA (pH 5.5) on silica gel 60 TLC plates, where 
the antibody construct remains at the baseline, while 
89Zr4+ ions and [89Zr]-EDTA elute with the solvent 
front. Purity was also assessed by 
size-exclusion-chromatography – high-performance- 
liquid-chromatography (SEC-HPLC) by using an 
isocratic method with 0.1 M phosphate buffer, pH=7 
as mobile phase and a flowrate of 1 mL/min.  
Flow cytometry, immuno-reactivity and 
stability measures 
The binding affinity of the different 
DFO-trastuzumab conjugates was evaluated using 
flow cytometry. In brief, 0.3x106 SK-OV-3 cells were 
incubated with increasing concentrations (0.39-100 
nM) of unlabeled trastuzumab, DFO-trastuzumab 
(random), DFO-trastuzumab (β-Gal) and 
DFO-trastuzumab (endoS2) for 1 hour at 4 ⁰C. Cells 
were washed twice in FACS buffer (1% BSA, 0.5 mM 
EDTA in PBS) and stained for 30 min at 4 ⁰C with 
AF488-anti-human IgG (#A11013, Life Technologies). 
Cell-associated fluorescent intensity was quantified 
using FACSCanto II (BD Biosciences, New Jersey, 
USA) and data analyzed using FlowJo Software 
(v10.0.7, Tree Star, OR, USA).  
The immuno-reactivity of the different versions 
of 89Zr-DFO-trastuzumab was assessed according to 
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the Lindmo assay [29]. Increasing concentrations of 
SK-OV-3 cells (1.25x106 – 4.5x107 cells/mL) were 
incubated with 6 nM 89Zr-DFO-trastuzumab for 3 
hours at 4 ⁰C. Cells were centrifuged at 500g for 5 
minutes and the supernatants and pellets counted in a 
gamma counter (Wizard2, PerkinElmer, MA, USA). 
Cell-associated radioactivity was calculated as the 
ratio of cell-bound radioactivity to the total amount of 
radioactivity added.  
 The in vitro stability of labeled probes was 
evaluated up to 7 days after radiolabeling in either 
PBS (4 ⁰C) or mouse plasma (37 ⁰C). A total of 2 MBq 
of 89Zr-DFO-trastuzumab was incubated with 0.5 mL 
PBS or plasma and a sample withdrawn at least every 
other day. The radiochemical stability in buffer and 
plasma was determined by radio-TLC as described 
above. 
Small animal PET/CT imaging 
Longitudinal small animal PET/CT imaging was 
conducted on an Inveon Multimodality PET/CT 
scanner (Siemens, Germany). Mice bearing SK-OV-3 
tumors (N=4/tracer) were injected intravenously 
immediately after EOS via the tail vein with 2.08 ± 0.2 
[range: 1.2 - 2.3] MBq 89Zr-DFO-trastuzumab 
(random, β-Gal and endoS2 variants) diluted in 0.9% 
sterile NaCl prior to injection (200 µL total volume). 
Concurrently, the protein dose was 8.9 ± 0.3 [range: 
6.4 - 13.2] µg. A group of mice received a co-injection 
of 100 µg (N=4/tracer) or 500 µg (N=4/tracer) 
unlabeled trastuzumab for random, β-Gal and endoS2 
89Zr-DFO-trastuzumab variants. For isotype control 
imaging, mice bearing SK-OV-3 tumors (N=4/tracer) 
were injected intravenously with 2.04 ± 0.02 [range: 
1.95 - 2.1] MBq 89Zr-DFO-IgG1 (random and endoS2 
variants) diluted in 0.9% sterile NaCl prior to injection 
(200 µL total volume). Concurrently, the protein dose 
was 8.9 ± 0.25 [range: 8.5 - 9.3] µg. Mice bearing PDX 
tumors were injected with 1.15 ± 0.18 MBq 
89Zr-DFO-trastuzumab (endoS2) diluted in 0.9% 
sterile NaCl prior to injection (200 µL total volume). 
Concurrently, the protein dose was 7.7 ± 0.26 [range: 
6.4 - 13.2] µg. 
Mice were anesthetized with sevoflurane (4% in 
65% N2, 35% O2) during PET/CT imaging. Static PET 
data was acquired in list mode at 24, 70 and 120 hours 
(acquisition time 300, 600 and 900 s respectively) 
post-injection (89Zr-DFO-trastuzumab and 
89Zr-DFO-IgG1). PET imaging in PDX models was 
conducted 70 hours post-injection (acquisition time 
600 s). Images were reconstructed using a 3D 
maximum a posteriori algorithm (MAP) with CT 
based attenuation correction. Image analysis (Inveon 
Software, Siemens) was performed by drawing CT 
based region of interests (ROIs). The uptake of 
89Zr-DFO-trastuzumab was quantified as % injected 
dose per gram tissue (%ID/g).  
Ex vivo biodistribution 
Mice were euthanized after the last imaging 
session and underwent conventional ex vivo 
biodistribution. Tumors and organs were resected, 
weighed and the radioactivity counted in a gamma 
counter (Wizard2, PerkinElmer). Tumors were fixed in 
4% paraformaldehyde for 24 hours and subsequently 
transferred to 70% ethanol for immunohistochemical 
analysis.  
Immunohistochemistry 
Formalin-fixed paraffin-embedded tumors were 
sectioned at 4 µm, deparaffinized, rehydrated and 
microwaved in citrate buffer pH=6 for epitope 
retrieval. Sections were blocked in 2% bovine serum 
albumin (BSA) in PBS and incubated with anti-ERBB2 
(#HPA001383, Sigma Aldrich) at 1:400 dilution for 1 
hour at room temperature. Primary antibody was 
detected using the EnVision+ System-HRP Labeled 
Polymer and Liquid DAB+ Substrate Chromogen 
System (Agilent Technologies, California, USA) and 
sections were counterstained with Mayer’s 
Hematoxylin (Region H Apotek, Denmark). Tumors 
from each group were stained in the same analysis 
and HER2 expression was graded according to the 
HercepTestTM Interpretation Manual (Agilent 
Technologies, CA, USA) [30]. 
Statistical analyses 
Data are expressed as mean ± SEM. The effect of 
conjugation method on tumor PET uptake was 
evaluated by 2-way ANOVA corrected for multiple 
comparisons (Tukey). One-way ANOVA with post hoc 
test corrected for multiple comparisons (Tukey) was 
applied to test for differences in tumor volumes and 
body weight between groups (randomization) and the 
effect of conjugation method on biodistribution. P 
values ≤ 0.05 were considered statistically significant. 
Statistical analyses were performed using GraphPad 
Prism 7.0c (California, USA). 
Results 
Antibody conjugation and radiolabeling  
Trastuzumab was successfully purified and 
conjugated to DFO by 4 alternate methods: randomly 
on lysine residues (random), site-specifically using 
ß-(1-4) galactosidase (β-Gal), site-specifically using 
endoglycosidase S2 (endoS2) or randomly after 
site-specific endoS2 cleavage (endoS2-R), (Figure 1A). 
The immuno-conjugates were labeled with 89Zr with a 
radiochemical yield of 37.4 ± 3.8, 32.6 ± 4.3, 23.9 ± 2.2 
and 22.7 ± 7.3 MBq, respectively. Human IgG1 was 
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labeled with a radiochemical yield of 32.0 (random) 
and 15.9 (endoS2) MBq. Radiochemical purity was 
assessed by radio-TLC and was >99% for all versions 
of 89Zr-DFO-trastuzumab and 89Zr-DFO-IgG1. Figure 
1B shows a representative SEC-HPLC chromatogram 
of endoS2 modified 89Zr-DFO-trastuzumab. Less than 
5% aggregation at EOS for all tracers were observed 
(data not shown). The specific activity of 
89Zr-DFO-trastuzumab was 279.1 ± 28.1 (random), 
243.3 ± 31.9 (β-Gal), 178.1 ± 16.4 (endoS2) and 169.4 ± 
54.5 (endoS2-R) MBq/mg. The specific activity of 
89Zr-DFO-IgG1 was 238.8 (random) and 227.1 
(endoS2) MBq/mg. DOL was 0-6 (random), 4 (β-Gal) 
and 2 (endoS2) as determined by mass spectrometry 
and was not determined for endoS2-R. See Table 1 for 
specifications of each tracer.  
In vitro evaluation of DFO-trastuzumab 
Following chelator conjugation, an in vitro 
binding assay was performed to investigate the effect 
of chelation methodology on affinity of trastuzumab 
towards HER2 (Figure 1C). Unlabeled trastuzumab, 
random, β-Gal and endoS2 modified 
DFO-trastuzumab all showed affinities in the 
nanomolar range. Unlabeled trastuzumab presented 
with a KD of 1.09 nM, randomly labeled trastuzumab 
1.55 nM and site-specific trastuzumab tracers (β-Gal 
and endoS2) both exhibited a KD of 1.45 nM.  
 
Table 1: Specification of tracers  
 89Zr-DFO-trastuzumab 89Zr-DFO-IgG1 
 Random ß-Gal EndoS2 EndoS2-R Random EndoS2 
Radiochemical 
yield (MBq) 
37.4 ± 3.8 32.6 ± 
4.28 
23.9 ± 2.19  22.7 ± 7.3 32.0 15.9 
Purity TLC (%) >99 >99 >99 >99 >99 >99 
Aggregates at EOS 
(%) 
≤ 5 ≤ 5 ≤ 5 ≤ 5 ≤ 5 ≤ 5 
Specific activity 
(MBq/mg) 
279.1 ± 
28.11 
243.3 ± 
31.92 
178.11 ± 
16.38 
169.40 ± 
54.48 
238.8 227.1 
Immunoreactivity 
(%) 
80 93 93 82 - - 
Activity injected 
(MBq) 
2.3 ± 0.04 2.2 ± 0.02 1.6 ± 0.06 2.2 ± 0.1  2.1 ± 0.08 2.0 ± 
0.05 
Protein dose 
injected (µg) 
8.5 ± 0.21 8.3 ± 0.18 8.9 ± 0.06 9.6 ± 0.44 8.9 ± 0.36 8.9 ± 
0.21 
Degree of labeling 0-6 4 2 - - - 
Values are mean ± SEM 
 
 
 
 
Figure 1: Radiochemistry and in vitro evaluation of 89Zr-DFO-trastuzumab. (A) Schematic illustration of the 4 alternate ways of DFO conjugation to trastuzumab: (1) 
randomly on lysine residues (random), site-specifically on enzymatically treated glycans using either (2) β-galactosidase (β-Gal) or (3) endoglycosidase S2 (endoS2), or randomly 
on lysine residues after endoS2 modification (endoS2-R). (B) Representative HPLC chromatogram of endoS2 modified 89Zr-DFO-trastuzumab after PD10 purification. (C) 
Median fluorescent intensity (MFI) of SK-OV-3 cells incubated with increasing concentrations of unlabeled, random, β-Gal and endoS2 modified trastuzumab. (D) Radio-TLC 
analysis of tracer stability in plasma and buffer up to 168 hours post-labeling.  
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 The in vitro binding characteristics of 
radiolabeled trastuzumab was also assessed by the 
cell-binding assay described by Lindmo et al. The 
immuno-reactive fraction was for both 
site-specifically labeled trastuzumab 93%, whereas 
the immuno-reactivity was 80% and 82% for 
randomly and endoS2-R labeled trastuzumab, 
respectively. The Lindmo binding data of all 
89Zr-DFO-trastuzumab tracers are depicted in Figure 
S1. 
89Zr-DFO complex of 89Zr-DFO-trastuzumab was 
stable in buffer for all tracers with >99% intact tracer 
after 168 hours of incubation (Figure 1D). This was 
also the case for β-Gal modified 
89Zr-DFO-trastuzumab in plasma, whereas 
89Zr-DFO-trastuzumab (endoS2) decreased to 91% 
and 89Zr-DFO-trastuzumab (random) decreased to 
80% after 168 hours in plasma.  
Increased uptake of site-specifically labeled 
trastuzumab in SK-OV-3 tumors 
The in vivo tumor targeting and distribution of 
the different 89Zr-DFO-trastuzumab conjugates were 
assessed by longitudinal PET/CT imaging in 
SK-OV-3 tumor-bearing mice randomized into 11 
groups (N=4/group). No difference in tumor volume 
was found between the groups at randomization 
(p=0.73), Figure S2. Mice were subjected to PET/CT 
imaging 24, 70 and 120 hours after injection of 
89Zr-DFO-trastuzumab. Representative images of 
mice from each group 70 hours post-injection clearly 
illustrate targeting of 89Zr-DFO-trastuzumab to the 
HER2 expressing SK-OV-3 tumors (Figure 2A). ROI 
analysis of PET images was used to quantify the 
temporal uptake in tumors (Figure 2C&D) as well as 
in the heart, liver, kidney and muscle (Figure 2B).  
 
 
Figure 2: Longitudinal PET/CT imaging in SK-OV-3 xenograft bearing mice. (A) Representative coronal (top) and axial (bottom) images 70 hours post-injection of 
random, β-Gal, endoS2 and endoS2-R modified 89Zr-DFO-trastuzumab. Arrows designate the tumors. (B) Image-derived biodistribution of 89Zr-DFO-trastuzumab in major 
organs over the imaging time-course (N=4/tracer). (C) Mean and (D) maximum tumor uptakes at 24, 70 and 120 hours post-injection of tracers (N=4/tracer).  
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Mean (Figure 2C) and maximum (Figure 2D) 
tumor uptake values were highly dependent on 
which conjugation method was applied. For 
89Zr-DFO-trastuzumab (random) the accumulation in 
tumors increased from 5.9 ± 0.4 to 6.5 ± 0.5 %ID/g 
from the initial to the final time-points. Tumor uptake 
of site-specific probes increased from 10.1 ± 0.7 to 14.2 
± 1.7 %ID/g and 10.2 ± 0.7 to 16.7 ± 1.5 %ID/g for 
β-Gal and endoS2 labeled 89Zr-DFO-trastuzumab, 
respectively. Image-contrast did not increase beyond 
the 70-hour time-point for any of the tracers. 
Maximum tumor uptake values showed a similar 
profile, increasing from 15.8 ± 1.3 to 17.5 ± 1.5 %ID/g 
(random), 24.5 ± 2.7 to 43.5 ± 7.9 %ID/g (β-Gal) and 
29.6 ± 3.4 to 54.2 ± 7.6 %ID/g (endoS2). Compared 
with random labeling, site-specific labeling showed a 
higher tumor uptake when measured by PET 
(p<0.0001) at all time-points. Ex vivo IHC analysis in 
SK-OV-3 tumors revealed no difference in HER2 
expression between groups receiving random, β-Gal 
and endoS2 modified 89Zr-DFO-trastuzumab (Figure 
S3). 
Image-derived biodistribution throughout the 
imaging time-course (Figure 2B) indicated a slower 
clearance profile for site-specifically labeled 
trastuzumab when compared to randomly labeled 
trastuzumab. Both site-specific tracers (β-Gal and 
endoS2) presented with a similar pharmacokinetic 
profile with high retention in blood and highly 
perfused organs such as the liver and kidneys. Uptake 
in muscle was similar for all tracers. 
Ex vivo biodistribution and effect of 
dose-escalation  
Conventional ex vivo biodistribution was 
performed after the last imaging session. The ex vivo 
biodistribution confirmed the in vivo imaging results, 
with key differences in blood pool and tumor uptake 
among different versions of 89Zr-DFO-trastuzumab 
(Figure 3). Tumor-to-blood and tumor-to-muscle 
ratios 120 hours post-injection are listed in Table S1. 
Tumor uptake of site-specific probes was significantly 
higher (p<0.01) compared with randomly labeled 
89Zr-DFO-trastuzumab, presenting with 10.9 ± 1.3 
%ID/g (random), 24.1 ± 4.3 %ID/g (β-Gal) and 30.7 ± 
3.1 %ID/g (endoS2) at the 120-hour time-point. 
Further, tumor-to-muscle ratios were increased for 
site-specific variants (31.5 ± 4.8 and 49.9 ± 6.3 for β-Gal 
and endoS2, respectively) when compared to 
randomly labeled 89Zr-DFO-trastuzumab (23.3 ± 2.7). 
In addition, site-specific 89Zr-DFO-trastuzumab 
showed an elevated blood pool of 3.9 ± 1.4 %ID/g 
(β-Gal) and 5.8 ± 0.6 %ID/g (endoS2, p=0.011) 
compared to randomly labeled trastuzumab (2.13 ± 
0.3 %ID/g). The in vivo stability of probes was also 
confirmed by the fairly low amount of 89Zr residing in 
bone (~2%) for all the tracers, which contrasts greatly 
to the group receiving free 89Zr (14 %ID/g). 
Non-tumor non-specific uptake did not significantly 
differ between the probes except in terms of liver 
uptake (p=0.049, random vs. β-Gal). 
 
 
Figure 3: Ex vivo biodistribution. Ex vivo biodistribution 120 hours after 
injection of random, β-Gal, endoS2 and endoS2-R modified 89Zr-DFO-trastuzumab 
or free 89Zr in SK-OV-3 tumor-bearing mice (N=4/tracer).  
 
Co-injection with unlabeled trastuzumab did not 
alter the distribution of 89Zr-DFO-trastuzumab 
considerably for any of the probes at the 120-hour 
time-point (Table 2). Notably, the tumor uptake of 
89Zr-labeled trastuzumab variants was not affected by 
antibody dose in the tested range apart from the 
tumor-to-muscle ratio of endoS2 that decreased from 
49.9 ± 6.3 to 27.7 ± 4.1 with 500 µg co-dose (Table S1). 
 
Table 2: Protein dose-escalation ex vivo biodistribution of 
89Zr-DFO-trastuzumab 
 Organs (%ID/g) 
 Blood Bone Heart Kidneys Liver Lungs Muscle Spleen Tumor 
Random 2.13 ± 
0.3 
2.82 ± 
0.2 
0.84 ± 
0.1 
1.55 ± 
0.1 
3.24 ± 
0.2 
1.34 ± 
0.1 
0.4 ± 
0.1 
2.08 ± 
0.2 
10.9 ± 
1.3 
Random+100 
µg 
1.66 ± 
0.3 
2.71 ± 
0.2 
0.97 ± 
0.1 
1.81 ± 
0.2 
3.22 ± 
0.2 
1.21 ± 
0.1 
0.54 ± 
0.1 
4.56 ± 
0.6 
10.4 ± 
0.8 
Random+500 
µg 
3.13 ± 
0.5 
2.58 ± 
0.2 
1.17 ± 
0.1 
1.88 ± 
0.1 
2.54 ± 
0.2 
1.97 ± 
0.2 
0.43 ± 
0.1 
2.83 ± 
0.6  
9.9 ± 
1.0 
β-Gal 3.90 ± 
1.4 
2.45 ± 
0.5 
1.34 ± 
0.2  
2.12 ± 
0.2 
7.11 ± 
1.8 
1.81 ± 
0.3 
0.89 ± 
0.2 
5.44 ± 
2.7 
24.1 ± 
4.3 
β-Gal+100 
µg 
3.8 ± 
1.1 
2.26 ± 
0.1 
1.49 ± 
0.2 
2.02 ± 
0.2 
4.5 ± 
0.2 
2.16 ± 
0.5 
0.78 ± 
0.1 
4.3 ± 
0.8 
25.2 ± 
1.6 
β-Gal+500 
µg 
6.58 ± 
1.1 
1.92 ± 
0.6 
2.14 ± 
0.2 
2.34 ± 
0.2 
3.42 ± 
0.2 
2.86 ± 
0.4 
0.81 ± 
0.2 
4.66 ± 
0.6 
24.4 ± 
1.9 
EndoS2 5.8 ± 
0.6 
2.71 ± 
0.3 
1.63 ± 
0.1 
2.23 ± 
0.2 
4.64 ± 
0.4 
2.6 ± 
0.4 
0.66 ± 
0.1 
3.43 ± 
0.1 
30.7 ± 
3.1 
EndoS2+100 
µg 
5.42 ± 
1.1 
2.32 ± 
0.4 
1.93 ± 
0.1 
2.57 ± 
0.3  
2.77 ± 
0.2 
2.8 ± 
0.4 
1.0 ± 
0.3 
2.93 ± 
0.5 
28.3 ± 
2.9  
EndoS2+500 
µg 
6.1 ± 
0.2 
2.7 ± 
0.1 
2.14 ± 
0.1 
2.86 ± 
0.2 
3.1 ± 
0.5 
3.42 ± 
0.2 
1.0 ± 
0.2 
8.14 ± 
2.0 
24.4 ± 
1.9 
Values are mean ± SEM 
 
HER2 expression across PDX models detected 
by site-specific 89Zr-DFO-trastuzumab 
The ability of randomly labeled 
89Zr-DFO-trastuzumab to reliably detect and quantify 
HER2 expression has previously been well 
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characterized both preclinically [5,31] as well as 
clinically [7,32]. To verify that site-specific 
89Zr-DFO-trastuzumab possesses similar targeting 
properties, endoS2 modified 89Zr-DFO-trastuzumab 
PET/CT imaging was applied to a panel of PDX 
models with varying HER2 expression (Figure 4). 
Site-specific 89Zr-DFO-trastuzumab was evaluated at 
the optimal imaging time-point (70 hours 
post-injection) and successfully detected HER2 
expression in the ST1616B (breast), ST2789B (breast), 
ST928B (breast), ST562 (gastric) and ST518 (breast) 
model (N=2-3/model). Representative PET/CT 
images and immunohistochemical sections stained for 
HER2 from the same mouse are presented in Figure 
4A. Quantitative ROI analysis revealed an average 
tumor uptake of 5.3 ± 0.6, 5.8 ± 0.8, 11.8 ± 3.1, 13.3 ± 1.1 
and 15.0 ± 1.8 %ID/g for the ST518, ST562, ST928B, 
ST2789B and ST1616B model respectively (Figure 4B). 
High HER2 expression was observed for the ST1616B 
model (HER2 3+), moderate expression for the 
ST2789B and ST562 (HER2 2+) models and lowest 
expression was observed for the ST928B (HER2 1+) 
and ST518 (HER2 0+) PDX models. Although not 
correlating directly, the highest in vivo tumor uptake 
of 89Zr-DFO-trastuzumab (endoS2) was overall 
detected in ST1616B and ST2789B, intermediate 
uptake in ST928B and ST562 models and the lowest 
uptake in the ST518 model.  
EndoS2 cleavage does not alter stability and 
uptake of randomly labeled trastuzumab 
We assessed whether enzymatic cleavage prior 
to random labeling of trastuzumab affected the 
distribution and tumor uptake of 
89Zr-DFO-trastuzumab (endoS2-R) since glycosylation 
in the Fc region is known to influence the stability of 
monoclonal antibodies. Mean tumor uptake of 
endoS2-R modified 89Zr-DFO-trastuzumab was 4.2 ± 
0.3, 5.1 ± 0.2 and 4.7 ± 0.3 %ID/g for the 24, 70 and 
120-hour time-point, respectively. Maximum tumor 
uptake was 13.1 ± 1.1, 13.7 ± 1.2 and 11.9 ± 0.7 %ID/g 
for the 24, 70 and 120-hour time-point respectively. 
EndoS2 modification of trastuzumab prior to random 
DFO conjugation did not alter either tumor uptake 
(Figure 2C&D) or distribution of the tracer (Figure 
2B). Instead, a similar uptake pattern when compared 
to the randomly labeled trastuzumab was observed 
(p=0.1095). Concordantly, 89Zr-DFO-trastuzumab 
(endoS2-R) presented with an immuno-reactive 
fraction of 82% (Figure S1D). 
Site-specific labeling and PET/CT imaging of 
isotype control matched antibody 
The non-specific uptake of randomly versus 
site-specifically labeled probes (endoS2) was 
evaluated by PET/CT imaging with an isotype 
control matched antibody (human IgG1) in SK-OV-3 
tumor-bearing mice. Mice were subjected to PET/CT 
imaging 24, 70 and 120 hours after injection of 
89Zr-DFO-IgG1. ROI analysis of PET images was used 
to quantify the temporal uptake in tumors (Figure 
S4A&B) as well as heart, liver, kidney and muscle 
(Figure S4C). 
 
 
Figure 4: Site-specific 89Zr-DFO-trastuzumab PET/CT imaging in PDX 
models with varying HER2 expression. (A) Representative axial PET/CT images 
of 89Zr-DFO-trastuzumab (endoS2) tumor uptake in ST518 (breast), ST562 (gastric), 
ST928B (breast), ST2789B (breast) and ST1616B (breast) PDX models 70 hours 
post-injection (left). Corresponding ex vivo HER2 immunohistochemical (IHC) 
analysis of same mouse (right). (B) Quantitative mean and maximum uptake of endoS2 
modified 89Zr-DFO-trastuzumab in tumors of the various PDX models 70 hours 
post-injection (N=2-3/model). 
 
 A decrease in the tumor uptake was observed 
for both probes over the imaging time-course. Mean 
tumor uptake of 89Zr-DFO-IgG1 (random) decreased 
from 3.3 ± 0.4 to 0.78 ± 0.09 %ID/g from the 24 to the 
120-hour time-point. Similarly, mean tumor uptake of 
89Zr-DFO-IgG1 (endoS2) decreased from 3.3 ± 0.2 to 
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0.9 ± 0.05 %ID/g. Maximum tumor uptake of 
89Zr-DFO-IgG1 decreased from 9.3 ± 2.0 to 1.8 ± 0.2 
(random) and from 7.6 ± 0.6 to 2.0 ± 0.2 %ID/g 
(endoS2) from 24 to 120 hours post-injection. No 
difference in mean (p=0.8241) and maximum 
(p=0.4120) tumor uptake was observed at all 
time-points. Image-derived biodistribution revealed a 
similar profile between randomly and site-specifically 
labeled 89Zr-DFO-IgG1 with retention in blood, liver 
and kidneys slowly clearing throughout the imaging 
time-course (Figure S4C). Ex vivo biodistribution 
confirmed the in vivo imaging results and no 
difference in uptake was found between the probes 
(p>0.6395) except in the liver (p=0.03), Figure S4D. 
Discussion 
The remarkable ability of 89Zr-labeled mAbs to 
monitor the performance of antibody-based 
therapeutics makes 89Zr-immuno-PET a much-desired 
platform to predict the response to such agents, which 
are increasingly used in the clinic. This is true for both 
the drug development phase as well as an individual 
companion diagnostic. Accordingly, the significance 
of manufacturing more robust and reproducible 
conjugates by ways of specific labeling strategies 
becomes apparent. In the present study, the 
monoclonal antibody trastuzumab (Herceptin®) was 
used as a model antibody to assess the effect of 
site-specific radiolabeling on tumor uptake, 
biodistribution, stability and immuno-reactivity in a 
HER2-positive ovarian cancer mouse model.  
Different strategies utilizing glycan remodeling 
by enzymatic approaches representing different 
degrees of modification were used to yield different 
conjugates. Initially, the conjugates were 
characterized in vitro and site-specific probes 
exhibited superior in vitro behavior with increased 
plasma stability and immuno-reactivity. The 
immuno-reactivity of the randomly labeled version 
was found to be 80%, which is in line with previous 
reports in the literature [5]. Preserved reactivity 
towards target is of outmost importance to reliably 
predict the distribution of the parent therapeutic 
antibody, emphasizing a clear benefit of site-specific 
labeling.  
In the current study, site-specific versions by 
both the endoS2 and β-Gal method demonstrated 
significantly higher tumor uptakes when compared to 
the randomly labeled version. Tumor uptake in the 
SK-OV-3 model was nearly twice as high for the 
site-specific conjugates, 14.2 ± 1.7 %ID/g (β-Gal) and 
16.7 ± 1.5 %ID/g (endoS2), compared to 6.5 ± 0.5 
%ID/g for the random labeled trastuzumab 120 hours 
post-injection. In some preclinical model systems 
however, the site-specific approach for immuno-PET 
imaging has not shown superiority to the traditional 
conjugation strategies [22,25,27]. One contributing 
factor could be the specific antibody and/or mouse 
model used. One could imagine, that the added value 
of a site-specifically mAb conjugated far from the 
antigen-binding region for in vivo PET imaging, is as 
diverse as the antibody itself. To our knowledge, this 
is the first report on the impact of site-specific labeling 
of trastuzumab by glycan remodeling for imaging 
purposes. Indeed, more antibodies need to be 
evaluated in order to support, confirm or refute that 
site-specific labeling in general will improve 
immuno-PET imaging.  
In terms of accumulation in off-target organs, the 
four variants behaved similarly. Notably, the similar 
accumulation observed in bone between the probes 
highlights that the differences in stability cannot be 
credited to the transchelation of 89Zr. A tendency 
towards higher retention of site-specific tracers in 
spleen and kidney was observed. Also, the ex vivo 
biodistribution data showed a significantly higher 
liver accumulation of site-specifically labeled (β-Gal) 
compared to randomly labeled 
89Zr-DFO-trastuzumab. Being major clearance routes 
for high-molecular weight complexes, the higher risk 
of aggregation when perturbing the glycosylation 
state [33] could be the reason for increased liver, 
kidney and spleen uptake for site-specific versions of 
89Zr-DFO-trastuzumab. Contrasting to this, is the 
increased blood pool of site-specific tracers compared 
to the randomly labeled version, and the higher 
activity is thus more likely to be attributed to the 
highly-perfused nature of these organs.  
The PET imaging data was strongly supported 
by the ex vivo biodistribution data with major 
differences primarily in terms of tumor uptake. 
Moreover, the differences in blood pool at the 
120-hour time-point is in line with the in vitro stability 
of compounds in plasma, indicative of site-specific 
tracers outperforming the randomly labeled version. 
With different labeling strategies and aiming for equal 
mass protein dose injected, we speculated whether 
the differential uptake pattern could be attributed to 
differences in specific activity. We therefore pursued 
the dose-escalation study. Co-injection with unlabeled 
trastuzumab did not considerably alter the 
distribution of 89Zr-DFO-trastuzumab, randomly or 
site-specifically labeled. A tendency towards 
increased circulation time with increased dose was 
observed for all tracers, as expected for circulating 
IgGs. This was also confirmed by the tumor-to-blood 
ratios at different protein doses. Notably, the tumor 
uptake was unaffected of antibody dose, highlighting 
that the tumor uptake was not specific 
activity-dependent in the investigated range. 
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However, a blocking tendency was observed for 
endoS2 modified 89Zr-DFO-trastuzumab with higher 
protein doses. 
Compared to other immuno-PET radiotracers 
developed for targeting HER2, the observed tumor 
uptake for randomly labeled 89Zr-DFO-trastuzumab 
(6.5 ± 0.5 %ID/g) is generally lower than previously 
reported. Dijkers et al. [5] stated a mean tumor uptake 
of 30-33 %ID/g in SK-OV-3 tumor-bearing xenografts 
6 days post-injection. Likewise, Tinianow et al. [22] 
demonstrated a mean tumor uptake of 18.9-25.6 
%ID/g in BT-474 (HER2 3+) xenografts 6 days 
post-injection. Despite these immediate differences in 
tumor uptake, the tumor-to-blood ratio of 6.5 
observed 5 days post-injection (100 µg co-injection) in 
the present study is quite similar to the 7.6 and 5.1-7.1 
observed 6 days post-injection as obtained by Dijkers 
and Tinianow, respectively. Furthermore, Dijkers et 
al. also found the tumor uptake to be independent of 
antibody dose in a similar range as we applied in this 
study.  
With the noticeable impact of conjugation 
method on tumor uptake values, we were questioning 
whether this exclusively could be attributed to the 
differences in immuno-reactivity. The glycosylation 
state of the heavy chain N-linked glycans plays an 
important role in complement-dependent cytotoxicity 
(CDC) and antibody-dependent cell-mediated 
cytotoxicity (ADCC), through the Fcγ receptor (FcγR). 
Deglycosylated IgG no longer bind the FcγR and 
trigger CDC nor ADCC [34,35], opening an 
opportunity for site-specific trastuzumab by glycan 
modification alone to avoid immune recognition and 
reside in the blood for a prolonged period. The 
involvement of IgG-Fc in IgG recycling through the 
neonatal Fc receptor (FcRn) contrasts to this however, 
which is thought to be independent of Fc 
glycosylation [36]. To investigate the impact of 
enzymatic digest of the Fc glycans, we performed a 
control experiment with endoS2 representing the 
largest degree of modification in this study. The fact 
that endoS2 modification prior to random labeling did 
not result in superior tumor-targeting properties or 
distribution compared to the randomly labeled 
version, indicates that the major differences between 
the probes are to be found in the antigen-binding 
region. The flow cytometry of trastuzumab and 
DFO-trastuzumab (random, β-Gal and endoS2) 
slightly supported this notion with lowest KD for 
randomly labeled trastuzumab, although the 
differences were not prominent.  
Additional control experiments with an isotype 
control matched antibody supported the 
above-described findings of endoS2 modified and 
concurrently randomly labeled trastuzumab. Glycan 
modification of human IgG1 using endoS2 did not 
alter the distribution of tracer compared with 
randomly labeled IgG1 and the tumor uptake of both 
versions was low. This means that roughly ~3-4 
%ID/g of the observed mean 89Zr-DFO-trastuzumab 
uptake can be attributed to non-specific uptake or the 
enhanced permeability and retention (EPR) effect 
[37,38]. The in vivo biodistribution suggests that the 
89Zr-DFO-IgG1 tumor uptake is most likely due to the 
latter with uptake values similar to that of blood. 
These results are also in line with the tumor uptake of 
89Zr-DFO-trastuzumab (endoS2) in ST518 PDX tumors 
(~5 %ID/g) that are considered HER2 negative (HER2 
0+). 
The significance of site-specific labeling of mAbs 
extends beyond molecular imaging purposes. The 
synthesis and production of efficacious ADCs 
currently suffers from instability in the circulation and 
thus off-target toxicity as well as a large variation in 
cytotoxic payloads. In the case of trastuzumab-based 
ADCs, a trastuzumab-maytansine coupled by 
conventional lysine chemistry has been shown to 
exhibit a shorter biological half-life than various 
site-specific versions [39]. Indeed, the benefits of 
site-specific labeling are antibody-dependent. 
Nonetheless, by utilizing the site-specific approach 
the impact of introduction of a chelator on 
immuno-reactivity, stability and biodistribution is 
minimized. Adding to this, the site-specific 
methodology undeniably offers a route to 
reproducible, well-defined radioimmuno-conjugates 
for in vivo imaging. 
Conclusions  
To the best of our knowledge, this is the first 
report on the impact of site-specific labeling of 
trastuzumab by the SiteClickTM technology for 
immuno-PET. Site-specifically labeled 89Zr-DFO- 
trastuzumab displayed good in vitro characteristics 
with increased stability and immuno-reactivity when 
compared to 89Zr-DFO-trastuzumab conjugated by 
conventional lysine chemistry. Furthermore, 
site-specific 89Zr-DFO-trastuzumab exhibited superior 
tumor-targeting properties in the SK-OV-3 model and 
was well-matched for the specific immuno-PET 
imaging of HER2-positive PDX tumors. 
89Zr-DFO-trastuzumab variants by the β-galactosidase 
and endoglycosidase S2 approach are suitable for 
clinical manufacturing and together, these findings 
support the further development of site-specifically 
radiolabeled mAbs for immuno-PET. 
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cell-mediated cytotoxicity; ADCs: antibody-drug- 
conjugates; ANOVA: analysis of variance; BSA: 
bovine serum albumin; CDC: complement-dependent 
cytotoxicity; CT: computed tomography; DAB: 
3,3′-Diaminobenzidin; DFO: desferrioxamine; 
DIBO-DFO: dibenzocyclooctyne-desferrioxamine; 
DMSO: dimethyl sulfoxide; endoS2-R: endoglyco-
sidase S2-Random; EDTA: ethylenediaminetetraacetic 
acid; endoS2: endoglycosidase S2; EOS: 
end-of-synthesis; FACS: fluorescence activated cell 
sorting; FBS: fetal bovine serum; Fc: fragment 
crystallizable region; FcRn: fc recptor; FcγR: Fcγ 
receptor; GalT: galactose-1-phosphate uridyl 
transferase; HER2: human epidermal growth factor 
receptor 2; HPLC: high-performance liquid 
chromatography; IgG: immunoglobulin G; IHC: 
immunohistochemistry; IRF: immuno-reactive 
fraction; mAb: monoclonal antibody; MBq: mega 
becquerel; MFI: median fluorescent intensity; MnCl2: 
manganese chloride; NaHCO3: sodium bicarbonate; 
Na2CO3: sodium carbonate; NaCl: sodium chloride; 
PBS: phosphate buffered saline; PDX: patient-derived 
xenograft; PET: positron emission tomography; 
p-SCN-Bn-DFO: desferrioxamine-p-benzyl-isothio-
cyanate; radio-TLC: radio-thin-layer chromatography; 
ROIs: region of interests; SEC-HPLC: size-exclusion 
chromatography – high-performance liquid 
chromatography; SEM: standard error of mean; ß-Gal: 
ß-(1-4) galactosidase; HRP: horseradish peroxidase; 
TBS: tris-buffered saline; TLC: thin-layer 
chromatography; UDP-GalNAz: uridine 5′-diphos-
pho-N-azidoacetylgalactosamine tetraacylated. 
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